01—Abstract
Summary
Summary of the 8-K filed September 4, 2025. Cited figures are marked; the original filing is the authoritative source.
Boston Scientific Corporation (BSX) has filed an 8-K report announcing the upcoming retirement of Jeffrey B.
Mirviss, Executive Vice President and President of Peripheral Interventions, effective December 1, 2025. Mr. Mirviss will transition to a senior advisor role until February 27, 2026, continuing to receive his current base salary during this period. This transition is significant as it marks the departure of a key executive from a prominent division within the company.
Investors should note that the retirement is not unexpected and Mr. Mirviss is providing a transition period as a senior advisor. The company anticipates entering into a Retirement Agreement that will align with existing executive retirement plans, bonus structures, and long-term incentive programs.
This suggests a structured and planned handover, with compensation and benefits adhering to established company policies. While the departure of a senior leader warrants attention, the outlined transition plan aims to ensure continuity within the Peripheral Interventions division.
02—Key points
Key Highlights
- Jeffrey B. Mirviss, EVP and President of Peripheral Interventions, will retire effective December 1, 2025.
- Mr. Mirviss will serve as a senior advisor from December 1, 2025, through February 27, 2026.
- During his advisory role, Mr. Mirviss will receive a prorated base salary of $705,000 annually.
- A Retirement Agreement is expected to be executed, detailing payments and benefits consistent with company plans.
- The retirement and transition are subject to the terms of the Company's Executive Retirement Plan, 2025 Annual Bonus Plan, and Long-Term Incentive Program.
- The filing indicates a planned and structured departure of a key executive.
03—Questions
Frequently Asked Questions
What is the significance of Jeffrey B. Mirviss's retirement?
Jeffrey B. Mirviss holds the position of Executive Vice President and President of Peripheral Interventions, a key division for Boston Scientific. His retirement signifies a leadership change within this important segment of the company.
Will Mr. Mirviss be involved with the company after his retirement date?
Yes, Mr. Mirviss is expected to serve as a senior advisor to the Company from his retirement date of December 1, 2025, through February 27, 2026, to ensure a smooth transition.
What compensation and benefits can Mr. Mirviss expect?
Mr. Mirviss will continue to receive his current annual base salary of $705,000, prorated through his retirement date, while serving as a senior advisor. His retirement package will be governed by a Retirement Agreement, expected to be materially consistent with the terms of Boston Scientific's Executive Retirement Plan, 2025 Annual Bonus Plan, and Long-Term Incentive Program.
Does this retirement indicate any financial distress or operational issues for Boston Scientific?
Based on the provided filing, this appears to be a planned retirement of a senior executive, with a structured transition plan and benefits aligned with existing company programs. There is no indication in this filing of financial distress or operational issues.
04—Continue